🔗 Visit the ClinicalTrials.gov page for NCT00923845
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. | J Clin Oncol | 2005 | 3.15 |
| 2 | Epidemiologic aspects of renal cell carcinoma. | Semin Oncol | 2006 | 1.50 |
| 3 | Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. | J Exp Clin Cancer Res | 2014 | 1.39 |
| 4 | Trial watch: Chemotherapy with immunogenic cell death inducers. | Oncoimmunology | 2012 | 1.33 |
| 5 | Prognostic factors in renal cell carcinoma. | Semin Oncol | 2006 | 1.07 |
| 6 | Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. | Clin Cancer Res | 2011 | 1.04 |
| 7 | High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. | Clin Cancer Res | 2015 | 0.78 |
| 8 | Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. | Expert Opin Biol Ther | 2011 | 0.77 |